SAB Biotherapeutics, Inc.SABSEarnings & Financial Report
Nasdaq
SABS Q4 2024 Key Financial Metrics
Revenue
$114.7K
Gross Profit
N/A
Operating Profit
$-10.0M
Net Profit
$-11.4M
Gross Margin
N/A
Operating Margin
-8726.3%
Net Margin
-9934.5%
YoY Growth
-62.4%
EPS
$-1.23
Financial Flow
SAB Biotherapeutics, Inc. Q4 2024 Financial Summary
SAB Biotherapeutics, Inc. reported revenue of $114.7K for Q4 2024, with a net profit of $-11.4M (-9934.5% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $114.7K |
|---|---|
| Net Profit | $-11.4M |
| Gross Margin | N/A |
| Operating Margin | -8726.3% |
| Report Period | Q4 2024 |
SAB Biotherapeutics, Inc. Annual Revenue by Year
SAB Biotherapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $1.3M).
| Year | Annual Revenue |
|---|---|
| 2024 | $1.3M |
| 2023 | $2.2M |
| 2022 | $23.9M |
Income Statement
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $581101 | $85518 | $1.3M | $305011 | $944575 | $263137 | $0 | $114698 |
| YoY Growth | -95.1% | -98.7% | -64.7% | -85.9% | 62.5% | 207.7% | N/A | -62.4% |
Balance Sheet
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $42.7M | $35.4M | $28.3M | $83.9M | $71.4M | $61.9M | $53.8M | $44.2M |
| Liabilities | $18.3M | $15.7M | $13.1M | $26.6M | $18.5M | $15.8M | $16.9M | $18.2M |
| Equity | $24.4M | $19.7M | $15.3M | $57.3M | $52.8M | $46.1M | $36.9M | $26.0M |
Cash Flow
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-1.6M | $-4.9M | $-5.2M | $-13.4M | $-10.8M | $-7.7M | $-6.3M | $-9.5M |